Back

Respiratory Disease: UK Market Trends, Insights and Opportunities

This MedTech NAVIGATOR Report provides a landscape assessment of the innovations under development in the area of respiratory disease.

This MedTech NAVIGATOR Report provides a landscape assessment of the innovations under development in the area of respiratory disease. 

The report will be relevant to SMEs based in the UK and to those based further afield.

  • Respiratory disease affects approximately 20% of people and is the third biggest cause of death in England.
  • Lung cancer, pneumonia and chronic obstructive pulmonary disease (COPD) are the biggest causes of death.
  • Respiratory disease is identified as a clinical priority in the NHS Long Term Plan.
  • It is estimated that 12.7 million people in the UK are living with respiratory disease and lung conditions are estimated to cost around £9.9 billion each year.

Key findings of the report:

  • A new wave of digital ‘smart’ inhalers are coming onto the market. A major challenge will be integrating these into the current NHS pathway.
  • We provide an up to date analysis of what respiratory disease innovation have been funded by Innovate UK, SBRI and NIHR i4i awards.
  • Case studies on four medtech companies to watch:
    • Aseptika Limited (Activ8rlives)
    • Cambridge Respiratory Innovations Limited (CRiL)
    • My mHealth
    • Owlstone

Read the entire white paper here